The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion

NCT00709657 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Macular Degeneration
Regional Blood Flow
Vascular Endothelial Growth Factor

Interventions

DRUG: ranibizumab, bevacizumab or pegaptanib

Sponsor

Medical University of Vienna